Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933934 | 0.82 | ADRB2 (0.59) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL11072227 | 0.82 | ENPP2 (0.79) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL10511405 | 0.82 | HRH4 (0.56) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL2532397 | 0.82 | LMNA (0.78) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL11366419 | 0.81 | LMNA (0.51) | MAPTLMNAENPP2MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL28701756 | 0.80 | LMNA (0.75) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL11074729 | 0.78 | CYP11B1 (0.61) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL17916879 | 0.78 | HRH3 (0.68) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL5098007 | 0.78 | MAPT (0.62) | MAPTLMNAENPP2MKNK1MKNK2 | |
| SCHEMBL10512517 | 0.78 | DRD2 (0.50) | MAPTLMNAENPP2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999009845-A1 | IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| US-8901309-B2 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8822699-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178497-A1 | FUSED TRIAZOLES FOR THE TREATMENT OR PROPHYLAXIS OF MILD COGNITIVE IMPAIRMENT | BACE1, BACE2, APP | MAPT 13/4885LMNA 3452/4885ENPP2 3814/4885 |
| US-20120059030-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | MAPT 37/4885LMNA 2031/4885ENPP2 687/4885 |
| US-20140350260-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BACE1, BACE2, APP | MAPT 37/4885LMNA 2031/4885ENPP2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.